2025 Investor Conference

BIONIME CORPORATION

INVESTOR PRESENTATION

TWSE-4737

Disclaimer

- This presentation contains forward-looking statements reflecting the Company's current assessments and views, based on both subjective and objective factors, regarding its past, present, and future operations. Such forward-looking statements involve known and unknown risks, uncertainties, and assumptions, many of which are beyond the Company's control, and actual results may differ materially from those expressed or implied by such statements.
- The information contained herein represents the Company's current perspectives as of the date of this presentation and does not constitute any express or implied representation or warranty as to the accuracy, completeness, or reliability of such information. This presentation does not purport to provide a complete description of the Company, its industry, or any future developments.
- The Company undertakes no obligation to publicly update, revise, or otherwise notify any changes to any forward-looking statements, whether as a result of new information, future events, or otherwise.
- No part of this presentation may be reproduced, modified, redistributed, excerpted, transmitted, or used for any commercial purpose without the prior written consent of the Company.

Agenda

01
Company Overview
About BIONIME

02
Products & Technology
Global CGM Market Overview

RIGHTEST iFree CGM

03
Operational Overview
2025 Financial Report

04
Market Promotion
Sales & Marketing Operation

01 Company Overview

Company Profile

Established	April 2003
Public Listing	Listed on Taiwan Stock Exchange (TWSE) / Stock Code: 4737 / December 2010
Registered Capital	NT$673 million (Accumulated capital increase exceeds NT$3.0 billion)
Headquarters	Taichung City, Taiwan
Office and Factory	Building Space: 56,227 m^2 / Land area: 27,060 m^2
Core Business	Diabetes Glucose Management System

Global Presence



6 subsidiaries for global markets,
with products sold over 100 countries.

About BIONIME

- 11.9% of global healthcare expenditure (≈ US$1.0 trillion) is spent on diabetes care.
- 70–80% of costs are driven by diabetes complications.
- Effective glycemic management is key to preventing complications.

Founded in 2003, Bionime focuses on the research, development, design, manufacturing, and marketing of glucose management systems, integrating medical devices and cloud-based software through IoT to build a **Diabetes Care Ecosystem**.

RIGHTEST Diabetes Care Ecosystem

The **Human-Centered** Digital Diabetes Management Ecosystem integrates **IoT (Internet of Things) technology** with advanced digital solution

02 Products & Technology

CGM + BGM: Essential Tools for Diabetes Management

enables effective glucose control, reduces physical harm, and is essential for diabetes care.

CGM is like a
Video camera

Continuously tracks glucose trends
Provides real-time alerts for abnormal fluctuations



BGM is like a
camera

Snapshot measurements only
No monitoring when not measured

RIGHTEST™ iFree CGM

Continuous Glucose Data Without Frequent Finger Pricks

Clear glucose insights anytime, empowering healthier lifestyle decisions.

CGM: An enzymatic sensor with a soft needle inserted subcutaneously

24-hour real-time, continuous glucose monitoring

- ✓ Real-time, minute-by-minute glucose data
- ✓ Continuous trend visualization via mobile app
- ✓ Predictive alerts for hypo- and hyperglycemia



Unaware → Lifestyle Learning → Confident Control → Better Living

Continuous insights help users learn, adapt, and manage glucose with confidence.

RIGHTEST IFREE CONTINUOUS GLUCOSE MONITORING SYSTEM

RIGHTEST™ iFree CGM

CONFIDENTIAL 華廣生技 機密文件 非經授權 請勿使用

Time In Range (TIR) Percentage of Time within the Target Glucose Range

Higher TIR = Better Glucose Control

- Time spent within the target (green) range
- More green time reflects improved glucose management

Glucose Control Targets for Type 1 and Type 2 Diabetes



TIR > 70% →
to reduce the risk of complications

>180 mg/dL：Above target range → Hyperglycemia

Target range: 70–180 mg/dL

<70 mg/dL：Below target range → Hypoglycemia

Reference: https://diabetesjournals.org/care/article/42/8/1593/36184/Clinical-Targets-for-Continuous-Glucose-Monitoring

CGM Reduces the Risk of Diabetes Complications

After 6 Months of CGM Use

(Compared with Traditional Blood Glucose Monitoring, BGM)

1% ↓ HbA1c

15% ↓ Risk of Diabetes Complications



Achieving Early Glycemic Control Targets

(TIR > 70% → HbA1c < 7.0%)

The World Health Organization (WHO) calls for Preventing or Mitigating the Impact of Diabetes through Healthy Lifestyle Behaviors



Average healthcare expenditure for patients with diabetes is

3 times higher than that of the general population

Medical costs associated with **complications** increase by

5~10 times

11.9% of global healthcare expenditure is attributed to diabetes, with

80% driven by complications.

Global Paradigm Shift in Blood Glucose Monitoring

US

Federal healthcare insurance (Medicare) accounts for 21% of total U.S. healthcare expenditure.

CGM reimbursement is 32 times higher than BGM reimbursement (2024).



Allowed Charges	2017	2018	2019	2020	2021	2022	2023	2024
BGM Total	$211,921,145	$215,212,108	$180,580,859	$156,208,217	$119,818,443	$97,982,988	$79,823,807	$62,350,374
BGM Growth		1.55%	-16.09%	-13.50%	-23.30%	-18.22%	-18.53%	-21.89%
CGM Total	$11,681,171	$108,460,469	$278,853,601	$453,766,410	$692,124,004	$1,192,181,646	$1,384,773,731	$1,995,137,189
CGM Growth		828.5%	157.1%	62.7%	52.5%	72.2%	16.2%	44.1%
CGM /BGM		0.5	1.5	2.9	5.8	12.2	17.3	32.0

UK

CGM is reimbursed for patients with Type 1 diabetes, with adoption among patients with Type 2 diabetes reaching approximately 20%.

Compared with patients not using CGM, hospitalization rates among patients using CGM are reduced by approximately 60% in both type 1 and type 2 diabetes.



Industry Trends from Revenue Data of Market Leaders

No.1 Global BGM vs. No.1 Global CGM (Q1–Q3 2025 Revenue Comparison)

Estimated 2025 global BGM market value: USD 5.0–5.5 billion

Revenue: USD 1.1 billion (BGM YoY growth rate: - 2%)



The global CGM market value has exceeded the BGM market by more than 2 times.

Estimated 2025 global CGM market value: USD 13.0 billion

Revenue: USD 5.6 billion (CGM YoY growth rate: +19.4%)

(in millions)	September 30, 2025	September 30, 2024	Total Change
Established Pharmaceutical Products —			
Key Emerging Markets	$ 3,121	$ 2,910	7.3 %
Other Emerging Markets	1,033	1,016	1.7
Nutritional Products —			
International Pediatric Nutritionals	1,377	1,377	—
U.S. Pediatric Nutritionals	1,695	1,646	3.0
International Adult Nutritionals	2,334	2,146	8.8
U.S. Adult Nutritionals	1,105	1,115	(0.9)
Diagnostic Products —			
Core Laboratory	3,899	3,848	1.3
Molecular	376	384	(2.0)
Point of Care	448	441	1.7
Rapid Diagnostics	1,757	2,148	(18.2)
Medical Devices —			
Rhythm Management	1,944	1,766	10.1
Electrophysiology	2,034	1,824	11.5
Heart Failure	1,073	948	13.2
Vascular	2,212	2,112	4.7
Structural Heart	1,848	1,637	12.9
Neuromodulation	736	705	4.4
Diabetes Care	5,865	4,942	18.7

Excluding the effect of foreign exchange, total Medical Devices sales increased 12.4 percent in the first nine months of 2025, led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology. Higher Diabetes Care sales were driven by continued growth in Abbott's continuous glucose monitoring (CGM) systems. CGM systems sales totaled $5.6 billion and $4.7 billion in the first nine months of 2025 and 2024, respectively. Excluding the effect of foreign exchange, CGM systems sales increased 19.4 percent in the first nine months of 2025.

CGM systems sales totaled $5.6 billion in the first nine months of 2025

Core Competencies Required to Compete in the Global CGM Market



Patent Infringement Risk

Major players' patent portfolios cover over 85% of key markets

BIONIME CGM Patent Portfolio Protection

As of September 2025, BIONIME has filed **over 488 patent applications** across major global markets, including the United States, European Union, United Kingdom, China, Japan, South Korea, and Taiwan.

As of September 2025, BIONIME holds more than **316 granted patents** related to Continuous Glucose Monitoring (CGM) worldwide.

CGM Production: Self-Innovation and Integration

80+
Cross-disciplinary technologies

200+
Production processes

100+
Sensor biochemical processes

2000+
QC parameters

Automation and smart manufacturing

- 95% Automated equipment built in-house
- 139 Self-developed automated machines
- 100+ Online AOI QC inspections
- Unmanned, robot-based production line
- Smart manufacturing control system (CIM+MES)

- A WORK OF ART -

It took around 10 years, along with great dedication and all-around excellence



Rechargeable transmitter with eco-friendly design
(Over 5 years, reduces waste by eliminating 180 batteries, 180 Bluetooth ICs, and 180 PCBs)

Manufacturing Expansion Plan

Bionime plans to utilize **three floors of its existing factory** (**2,200 ping per floor × 3 floors**) for **CGM automated production lines**.

- The Board of Directors has approved automated manufacturing equipment with an annual capacity of 5 million units to support international demand following CE certification in Europe.
- A CGM cleanroom production facility has been established on the 6th floor, with capacity to scale in line with future business growth.
- Each floor supports up to 10 million CGM units annually, representing approximately 2.0% of global CGM market share.



CONFIDENTIAL 華廣生技 機密文件 非經授權 請勿使用

CGM
產品精進

iFree CGM

CGM **Product**
Enhancement

Product Enhancement

iFree vs. iFree2 CGM Feature Comparison



RIGHTEST iFree	Model	RIGHTEST iFree2
Bionime	Manufacturer	Bionime
18+	Indicated Age	2+
10 or 14 days	Sensor Wear Duration	15 days
2 H	Warm-up Time	1 H
8.8 %	MARD	8.4 %
Daily calibration	Calibration Method	Factory calibration (Optional calibration)
1 min	Measurement Interval	1 min
Two-piece system (rechargeable transmitter)	System Configuration	Two-piece system (rechargeable transmitter)



03 2025 Operational Overview

Financial Report

Unit: thousands of NTD

Item/Year	2020	2021	2022	2023	2024	2025.Q3
Net operating revenues	1,668,586	1,849,924	2,210,589	1,755,567	1,933,746	1,411,625
Gross profit from operations	749,125	783,131	1,004,126	715,650	768,383	458,918
Gross profit %	**45%**	**42%**	**45%**	**41%**	**40%**	**33%**
Operating expenses	728,004	707,837	872,709	728,989	923,570	553,198
Net operating income	21,121	75,294	131,417	(13,339)	(155,187)	(94,280)
Net operating income %	**1%**	**4%**	**6%**	**-1%**	**-8%**	**-7%**
Non-operating income and expenses	9,990	(709)	(44,934)	(18,536)	(30,524)	(37,298)
Profit(Loss)	63,520	89,325	91,820	6,531	(125,999)	(87,774)
Profit %	**4%**	**5%**	**4%**	**0.4%**	**-6.5%**	**-6%**
EPS	**1.06**	**1.45**	**1.50**	**0.10**	**(2.09)**	**(1.31)**

5-year quarterly revenue comparison

- The sales revenue for Q3, 2025, amounted to 458 million NTD, reflecting a decrease of 6.1% compared to the same quarter in 2024.
- Cumulative revenue for Q1–Q3 2025 declined by 1.4% year over year.



Sales Region



Product Sales



- **Meter**：12%~15%；**Strips**：61%~84%
- **Other**：3%~27%

04 Market Promotion

2025 CGM Taiwan Market Expansion

Deepening Healthcare Engagement

Enhance product awareness

Channel Expansion

Increase product penetration and sales

User Engagement

Improve adoption and sustained usage

RIGHTEST iFree CGM

2026 CGM Promotion: Continued Expansion Across Global and TW Markets

International Markets

- CDMO business model
- Distributor-led brand operations

Taiwan Market

- Continue expanding coverage across medical institutions
- Increase penetration through pharmacy chains and retail channels

Third-Party Integration

- Strengthen ecosystem integration
- Expand CGM applications

iFree2
TW & MDR

THANK YOU

BETTER HEALTH FOR MORE PEOPLE

BIONIME

華廣生技股份有限公司

BIONIME CORPORATION

No.100, Sec. 2, Daqing St., South Dist.,
Taichung City 40242, Taiwan (R.O.C.)

40242 台灣台中市南區大慶街二段100號

T. + 886 4 2369 2388
F. + 886 4 2261 7586

www.bionime.com